NASDAQ$PRCT
PROCEPT BioRobotics Corporation · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported strong third quarter results driven by increased U.S. revenues and system sales, and increased fiscal year 2022 total revenue guidance.
PROCEPT BioRobotics reported a strong third quarter with total revenue of $20.3 million, a 135% increase compared to the prior year period. The company increased its fiscal year 2022 total revenue guidance to approximately $72.5 million, representing 110% growth compared to 2021.
- Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year period
- U.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase of 95% compared to the prior year period
- U.S. handpiece and consumables revenue of $8.0 million for the third quarter of 2022, an increase of 267% compared to the prior year period
- Increased fiscal year 2022 total revenue guidance to approximately $72.5 million, representing growth of 110% compared to 2021
Headline financials
Revenue & EPS history
PROCEPT BioRobotics · Revenue · Quarterly
$20.3M
Revenue by segment
PROCEPT BioRobotics · $19.4M total across 4 segments · Q3 2022
- U.S. System Sales$9.81M+94.7%50.7%
- U.S. Consumables$8.02M+267.0%41.4%
- Intl. Consumables$791K+18.8%4.1%
- Intl. System Sales$743K+54.5%3.8%
Forward guidance
The Company projects revenue for the full year 2022 to be approximately $72.5 million, which represents 110% growth over the Company’s prior year revenue. The Company projects full year 2022 Gross Margin guidance to be in the range 50% to 51%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.3%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.6%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+40.6%
Q3 2024
Best reaction
-15.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.7% | +16.0% | +21.3% | |
| Q4 2025 | -15.2% | -5.7% | -5.3% | |
| Q3 2025 | +1.6% | -7.5% | +2.7% | |
| Q1 2025 | -5.6% | +1.1% | +3.0% | |
| Q4 2024 | +8.6% | -3.4% | -4.2% | |
| Q3 2024 | +40.6% | +34.2% | +41.5% | |
| Q2 2024 | -9.4% | -4.3% | +24.8% | |
| Q1 2024 | +16.5% | +15.9% | +25.3% | |
| Q4 2023 | +1.1% | +0.5% | +1.2% | |
| Q3 2023 | +21.7% | +22.5% | +39.5% | |
| Q2 2023 | -6.7% | -10.3% | -18.4% | |
| Q1 2023 | -15.0% | -20.1% | -10.9% | |
| Q4 2022 | +1.2% | -4.3% | -28.7% | |
| Q3 2022 | -9.9% | -8.4% | +5.8% | |
| Q2 2022 | +4.3% | +4.3% | +0.2% | |
| Q1 2022 | -5.1% | -17.9% | +19.5% | |
| Q4 2021 | +1.2% | +5.9% | +38.7% | |
| Q3 2020 | -2.2% | -4.5% | -28.0% | |
| Q4 2020 | -2.2% | -4.5% | -28.0% | |
| Q2 2021 | -2.2% | -4.5% | -28.0% | |
| Q1 2021 | -2.2% | -4.5% | -28.0% | |
| Q3 2021 | -4.4% | -3.9% | -29.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro